{"id":"W4412819491","doi":"10.1038/s41591-025-03867-5","title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"National Cancer Institute; EMD Serono; Ipsen; Servier; Astellas Pharma; Eisai; EUSA Pharma; Seagen; UroGen Pharma; F. Hoffmann-La Roche; Incyte; Daiichi Sankyo Europe; Exelixis; Merck KGaA; Gilead Sciences; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Axitinib; Sunitinib; Medicine; Hazard ratio; Renal cell carcinoma; Internal medicine; Pembrolizumab; Oncology; Clear cell renal cell carcinoma; Kidney cancer; Confidence interval; Biomarker; Cancer; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005063737,0.0004402908,0.001085104,0.000358398,0.0001912858,0.00001146736,0.0002657554,0.0004331442,0.0001131294],"category_scores_gemma":[0.0008000328,0.0002690469,0.000342742,0.0007408587,0.0004994945,0.00005443603,0.0001192012,0.0007394335,0.00000201945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002176293,"about_ca_system_score_gemma":0.0004460796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001246805,"about_ca_topic_score_gemma":0.00002521071,"domain_scores_codex":[0.9972904,0.0001951512,0.0007147082,0.0006164822,0.0007237066,0.000459563],"domain_scores_gemma":[0.9971554,0.001067517,0.0003416904,0.0007845241,0.0004276483,0.0002232014],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6636549,0.001177817,0.0004860813,0.001406679,0.000539558,0.000135692,0.0004389192,0.00001219051,0.3182327,0.0005544273,0.007684911,0.005676072],"study_design_scores_gemma":[0.6179642,0.01042076,0.007669358,0.0003771937,0.003173612,0.00001810317,0.001379097,0.0002343037,0.3501409,0.00008424639,0.008235993,0.0003022644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9599468,0.008195243,0.00008697157,0.002079828,0.002125075,0.002245628,0.0000936697,0.00004327812,0.02518348],"genre_scores_gemma":[0.9953739,0.000109393,0.0004010679,0.000248793,0.0005318119,0.00007141072,0.0001827538,0.00004801047,0.00303283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04569072,"threshold_uncertainty_score":0.9999762,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05595577496506752,"score_gpt":0.3804246357242225,"score_spread":0.3244688607591549,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}